181 related articles for article (PubMed ID: 31567948)
1. Rituximab in systemic sclerosis: A protocol for systematic review.
Caldas MMVF; Neto FAB; Azevedo KPM; Pimenta IDSF; Oliveira AKDSG; Piuvezam G
Medicine (Baltimore); 2019 Sep; 98(38):e17110. PubMed ID: 31567948
[TBL] [Abstract][Full Text] [Related]
2. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis.
de Figueiredo Caldas MMV; de Azevedo KPM; de França Nunes AC; de Oliveira VH; Pimenta IDSF; de Araújo IDT; Neto FAB; da Silveira Gonçalves de Oliveira AK; Piuvezam G
Adv Rheumatol; 2021 Feb; 61(1):15. PubMed ID: 33640020
[TBL] [Abstract][Full Text] [Related]
3. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.
Gernert M; Tony HP; Fröhlich M; Schwaneck EC; Schmalzing M
Front Immunol; 2021; 12():817893. PubMed ID: 35111167
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature.
Narváez J; Pirola JP; LLuch J; Juarez P; Nolla JM; Valenzuela A
Autoimmun Rev; 2019 Mar; 18(3):262-269. PubMed ID: 30639647
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
Borrirukwisitsak S; Tantayakom P; Katchamart W
Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for rapidly progressive juvenile systemic sclerosis.
Zulian F; Dal Pozzolo R; Meneghel A; Castaldi B; Marcolongo R; Caforio ALP; Martini G
Rheumatology (Oxford); 2020 Dec; 59(12):3793-3797. PubMed ID: 32442284
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis.
Moradzadeh M; Aghaei M; Mehrbakhsh Z; Arab-Bafrani Z; Abdollahi N
Clin Rheumatol; 2021 Oct; 40(10):3897-3918. PubMed ID: 33796953
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
He C; Li W; Xie Q; Yin G
Front Immunol; 2021; 12():820163. PubMed ID: 35116041
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis.
Yalçinkaya Y; Artim Esen B; Amikishiyev S; Aliyeva N; Gül A; Öcal L; Inanç M
Turk J Med Sci; 2023; 53(6):1704-1712. PubMed ID: 38813512
[TBL] [Abstract][Full Text] [Related]
17. Targeting very early systemic sclerosis: a case-based review.
Melissaropoulos K; Kraniotis P; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
Rheumatol Int; 2019 Nov; 39(11):1961-1970. PubMed ID: 31254002
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
[TBL] [Abstract][Full Text] [Related]
19. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Yoshizaki-Ogawa A; Asano Y; Kashiwabara K; Oba K; Sato S
J Dermatol; 2022 Jan; 49(1):179-183. PubMed ID: 34661314
[TBL] [Abstract][Full Text] [Related]
20. Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy.
Moazedi-Fuerst FC; Lackner A; Kreuzer SM; Eller K; Odler B; Kovacs G; Flick H; Talakic E; Hermann J; Venhoff N; Venhoff A; Hafner F; Brodmann M; Jud P; Yazdani-Biuki B; Husic R; Salmhofer W; Stradner MH; Graninger WB; Thiel J; Brezinschek HP
J Autoimmun; 2024 May; 147():103246. PubMed ID: 38788540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
